Compare CSCO & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSCO | NVO |
|---|---|---|
| Founded | 1984 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.1B | 269.6B |
| IPO Year | 1990 | N/A |
| Metric | CSCO | NVO |
|---|---|---|
| Price | $77.05 | $49.36 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 10 |
| Target Price | ★ $88.00 | $54.25 |
| AVG Volume (30 Days) | ★ 27.4M | 26.4M |
| Earning Date | 02-11-2026 | 02-04-2026 |
| Dividend Yield | 2.13% | ★ 2.48% |
| EPS Growth | ★ 22.12 | 1.77 |
| EPS | 2.78 | ★ 3.62 |
| Revenue | ★ $59,054,000,000.00 | $48,588,245,669.00 |
| Revenue This Year | $9.32 | N/A |
| Revenue Next Year | $5.07 | $4.39 |
| P/E Ratio | $27.64 | ★ $13.69 |
| Revenue Growth | ★ 9.00 | 6.43 |
| 52 Week Low | $52.11 | $43.08 |
| 52 Week High | $88.19 | $93.80 |
| Indicator | CSCO | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 44.73 | 41.12 |
| Support Level | $73.42 | $48.08 |
| Resistance Level | $88.19 | $50.07 |
| Average True Range (ATR) | 2.54 | 2.08 |
| MACD | -0.57 | -0.78 |
| Stochastic Oscillator | 23.23 | 33.02 |
Cisco Systems is the largest provider of networking equipment in the world and one of the largest software companies in the world. Its largest businesses are selling networking hardware and software (where it has leading market shares) and cybersecurity software such as firewalls. It also has collaboration products, like its Webex suite, and observability tools. It primarily outsources its manufacturing to third parties and has a large sales and marketing staff-25,000 strong across 90 countries. Overall, Cisco employs 80,000 people and sells its products globally.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.